<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cholinesterase inhibitors in the treatment of dementia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cholinesterase inhibitors in the treatment of dementia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cholinesterase inhibitors in the treatment of dementia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel Press, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Alexander, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 21, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2442724846"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cholinesterase inhibitors and <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> are the only currently available symptomatic medications for cognition and global functioning in patients with dementia. Cholinesterase inhibitors target the acetylcholine deficit arising from loss of neurons in the nucleus basalis of Meynert and its projections in patients with dementia. They are considered symptomatic therapies and are not believed to be neuroprotective or to alter the underlying disease trajectory. </p><p>This topic will discuss the use of cholinesterase inhibitors in the treatment of dementia. Topics on other aspects of the treatment of dementia include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5080.html" rel="external">"Management of the patient with dementia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86250.html" rel="external">"Care of patients with advanced dementia"</a>.)</p><p></p><p class="headingAnchor" id="H592818312"><span class="h1">INDICATIONS</span></p><p class="headingAnchor" id="H3105063603"><span class="h2">Alzheimer disease</span><span class="headingEndMark"> — </span>The majority of patients with newly diagnosed Alzheimer disease (AD) should be offered a trial of a cholinesterase inhibitor for symptomatic treatment of cognition and global functioning. The degree of expected benefit is modest, and therapy should not be continued indefinitely in patients who do not appear to be benefiting or who have significant side effects. There is no convincing evidence that cholinesterase inhibitors are neuroprotective or have the ability to alter the underlying disease trajectory. Specific recommendations for patients with AD are discussed separately. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Cholinesterase inhibitors'</a>.) </p><p class="headingAnchor" id="H1993832768"><span class="h2">Non-Alzheimer dementia syndromes</span><span class="headingEndMark"> — </span>Cholinesterase inhibitors are also suggested in most patients with dementia with Lewy bodies (DLB) and may have comparatively greater symptomatic benefits than are observed in patients with AD. (See  <a class="medical medical_review" href="/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies", section on 'Cholinesterase inhibitors'</a>.)</p><p>There is less consensus on the role of cholinesterase inhibitors in patients with other forms of dementia, and regulatory approval is more variable for non-AD diagnoses. Most of the studies of cholinesterase inhibitors have been performed in patients with a clinical diagnosis of AD, and data are more limited and less consistent for other forms of dementia. Although AD is by far the most common cause of dementia in older adults, evidence of mixed pathology at the time of autopsy is common, especially the combination of Alzheimer and vascular pathology [<a href="#rid1">1-3</a>]. Many experts therefore find it reasonable to offer a trial of a cholinesterase inhibitor in patients with a clinical diagnosis of other types of dementia, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular dementia (see  <a class="medical medical_review" href="/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia", section on 'Cholinesterase inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parkinson disease dementia (see  <a class="medical medical_review" href="/d/html/5089.html" rel="external">"Cognitive impairment and dementia in Parkinson disease", section on 'Cholinesterase inhibitors'</a>) </p><p></p><p>In the aggregate, trials have not provided support for the use of cholinesterase inhibitors for these indications:</p><p class="bulletIndent1"><span class="glyph">●</span>Preventing progression of mild cognitive impairment to dementia (see  <a class="medical medical_review" href="/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Acetylcholinesterase inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frontotemporal dementia (see  <a class="medical medical_review" href="/d/html/14139.html" rel="external">"Frontotemporal dementia: Treatment", section on 'Cognitive dysfunction'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dementia in patients with Huntington disease (see  <a class="medical medical_review" href="/d/html/4902.html" rel="external">"Huntington disease: Management", section on 'Cognitive impairment and dementia'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive impairment in patients with multiple sclerosis (see  <a class="medical medical_review" href="/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Cognitive impairment'</a>)</p><p></p><p>This approach is generally consistent with guidelines from multiple societies including the American Academy of Neurology [<a href="#rid4">4</a>], American Psychiatric Association [<a href="#rid5">5</a>], Canadian Consensus Conference [<a href="#rid6">6</a>], National Institute for Health and Care Excellence (NICE) [<a href="#rid7">7</a>], British Association for Psychopharmacology [<a href="#rid8">8</a>], and European Federation of Neurological Societies (EFNS) [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H2875487639"><span class="h1">CHOICE OF DRUG</span><span class="headingEndMark"> — </span>Three cholinesterase inhibitors are available for use in a variety of formulations:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">Donepezil</a>, available as a once-daily tablet and a once-daily disintegrating sublingual tablet</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">Galantamine</a>, available as a twice-daily tablet or solution and an extended-release once-daily capsule </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">Rivastigmine</a>, available as a twice-daily capsule, a twice-daily solution (in some regions), and a 24-hour transdermal patch</p><p></p><p>All have demonstrated efficacy compared with placebo, and a limited number of direct comparisons do not suggest major differences in efficacy or tolerability among the three drugs [<a href="#rid11">11-16</a>]. Selection of an agent is therefore based largely upon ease of use, individual patient tolerability, cost, and clinician and patient preference (<a class="graphic graphic_table graphicRef63284" href="/d/graphic/63284.html" rel="external">table 1</a>).</p><p>In a pragmatic, open-label trial of 196 older adults with possible or probable AD who were initiating treatment with a cholinesterase inhibitor at one of four memory care practices in the United States, patients were randomly assigned to <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>, or <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> using dosing and formulations at the discretion of the treating clinician [<a href="#rid15">15</a>]. At 18 weeks, rates of discontinuation for any reason (including study withdrawal/loss to follow-up) were similar for the three drugs (39, 53, and 59 percent, respectively; p = 0.06). The most common reasons for discontinuation were adverse events (56 percent) and cost (29 percent). Among the three drugs, donepezil was the most likely to be titrated to the maximum dose (53, 5, and 29 percent) and the least likely to be discontinued for cost-related reasons (0, 26, and 30 percent). Side-effect rates and profiles were largely similar among groups. Other studies have also found higher discontinuation rates for rivastigmine and similar rates for donepezil and galantamine [<a href="#rid11">11,17</a>].</p><p class="headingAnchor" id="H2504470462"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H293488633"><span class="h2">Contraindications and precautions</span><span class="headingEndMark"> — </span>Cholinesterase inhibitors enhance vagal tone and are contraindicated in patients with baseline bradycardia or known cardiac conduction system disease (eg, sick sinus syndrome, incomplete heart block) due to risk of syncope, falls, and fractures.</p><p>Caution should be used when any of the three drugs are used in combination with drugs that induce bradycardia or alter atrioventricular (AV) nodal conduction (eg, beta blockers, calcium channel blockers, <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a>). Specific drug interactions may be determined by use of the <a class="external" href="/drug-interactions">Lexicomp drug interactions</a> tool (Lexi-Interact) included with UpToDate.</p><p><a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">Galantamine</a> should not be used in patients with end-stage kidney disease or severe hepatic impairment, and the <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> patch requires dose adjustments for hepatic impairment and low body weight. </p><p class="headingAnchor" id="H219328800"><span class="h2">Specific drugs</span><span class="headingEndMark"> — </span>Although side effects are largely similar across drugs, dose and formulation vary among the three cholinesterase inhibitors. </p><p class="headingAnchor" id="H3"><span class="h3">Donepezil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">Donepezil</a> is the oldest cholinesterase inhibitor still in use and remains a preferred and widely prescribed drug in this class due to its once-daily dosing and ease of use. </p><p>The recommended starting dose of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> is 5 mg per day, increasing to 10 mg per day after four to six weeks. Donepezil is available in pill form and also as an oral disintegrating tablet for those unable or unwilling to swallow a pill. Because nightly dosing can be associated with vivid dreaming or nightmares, we typically start with morning dosing to avoid sleep disturbances and then switch to nightly dosing if daytime nausea occurs. </p><p>A 23 mg noncrushable tablet of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> is available, but evidence does not support a clinically important advantage to the higher dose and it is associated with increased side effects [<a href="#rid18">18</a>].</p><p>Gastrointestinal symptoms (upset stomach, nausea, diarrhea, anorexia) are the most common side effects with prolonged use of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, occurring in approximately 20 to 30 percent of patients [<a href="#rid15">15,19-22</a>]. Symptomatic bradycardia can occur and is also related to cholinergic toxicity [<a href="#rid23">23,24</a>]. Rare cases of rhabdomyolysis and/or neuroleptic malignant syndrome have been reported in postmarketing surveillance [<a href="#rid25">25</a>].</p><p>No dose adjustments are needed for renal or hepatic impairment.</p><p class="headingAnchor" id="H2845888338"><span class="h3">Galantamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">Galantamine</a> is available as a twice-daily tablet or solution and as a once-daily extended-release capsule. The latter is preferred unless patients cannot swallow capsules. </p><p>The recommended starting dose is 8 mg once daily (4 mg twice daily for immediate release), increasing to 16 mg once daily (8 mg twice daily for immediate release) after four weeks and then to a target maintenance dose of 24 mg once daily (12 mg twice daily for immediate release) after four more weeks.</p><p>Gastrointestinal symptoms (nausea, vomiting, diarrhea, anorexia, weight loss) are the most common adverse effects and may be more likely with <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a> than with <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>. Galantamine should be given with meals to decrease the risk of nausea. </p><p><a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">Galantamine</a> should not be used in patients with end-stage kidney disease or severe hepatic impairment. A maximum dose of 12 mg is advised in patients with moderate renal (creatinine clearance 9 to 59 mL/minute) or hepatic impairment.</p><p>The use of <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a> has been associated with increased mortality in patients with mild cognitive impairment [<a href="#rid26">26</a>] (see  <a class="medical medical_review" href="/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Acetylcholinesterase inhibitors'</a>). Increased mortality has not been observed in patients treated for AD, mixed dementia, or vascular dementia.</p><p class="headingAnchor" id="H4"><span class="h3">Rivastigmine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">Rivastigmine</a> is available in oral and transdermal formulations. The transdermal patch is preferred over the oral formulation because it has better tolerability and similar efficacy [<a href="#rid27">27</a>]. </p><p>Three dose levels of the transdermal patch are available: 4.6, 9.5, and 13.3 mg/24 hours. The recommended starting dose of 4.6 mg/24 hours can be titrated upwards every four weeks. The patch can cause skin irritation, and application sites should be rotated. Two trials have shown a possible dose effect, with greater cognitive improvement on some but not all outcome measures with higher-dose patches [<a href="#rid28">28,29</a>].</p><p>The transdermal patch should be used at the lowest dose only (4.6 mg/24 hours) in patients with mild to moderate hepatic impairment, and the patch has not been studied in patients with severe hepatic impairment. The lowest dose should also be used in patients with low body weight (&lt;50 kg).</p><p>If used, oral <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> should be given with food and titrated more slowly than the other drugs due to increased risk of nausea, vomiting, anorexia, and headaches. Rivastigmine pill or solution is started at 1.5 mg twice daily, increasing in two- to four-week intervals by 1.5 mg twice-daily increments. If treatment is interrupted for longer than several days, it should be restarted at the lowest daily dose and then titrated again [<a href="#rid30">30</a>]. One trial found that side effects of oral rivastigmine may be ameliorated and higher daily doses achieved when it is given three times a day, rather than twice daily [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H362013293"><span class="h2">Approach to common side effects</span><span class="headingEndMark"> — </span>An approach to some of the more common or expected side effects of cholinesterase inhibitors is presented below. Because the benefits of cholinesterase inhibitors are modest, clinicians should assess whether the patient is benefiting from the drug before persisting, and use caution to avoid prescribing cascades (ie, prescribing a new drug to treat an unrecognized adverse effect of an existing therapy). (See  <a class="medical medical_review" href="/d/html/3013.html" rel="external">"Drug prescribing for older adults", section on 'Prescribing cascades'</a>.) </p><p class="headingAnchor" id="H2011946174"><span class="h3">Nausea and diarrhea</span><span class="headingEndMark"> — </span>The most common side effects of cholinesterase inhibitors are gastrointestinal (primarily diarrhea, nausea, and vomiting). The toxicity is dose related and often resolves with time or dose reduction.</p><p>For oral <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a>, taking smaller doses more frequently or changing to a patch formulation may help. Both <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a> and oral rivastigmine should be taken with meals [<a href="#rid32">32</a>].</p><p><a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">Donepezil</a> seems to be less likely to cause gastrointestinal upset than the other two drugs, so switching to donepezil may be reasonable in patients who do not tolerate <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a> or <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a>.</p><p class="headingAnchor" id="H281312887"><span class="h3">Anorexia and weight loss</span><span class="headingEndMark"> — </span>Weight loss occurs more commonly with cholinesterase inhibitors than placebo, but the clinical importance of this effect can be difficult to determine in individual patients, as dementia itself is often associated with weight loss.</p><p>In a case-control study that included 1188 patients with dementia who were started on a cholinesterase inhibitor (mostly <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> and <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>) and 2189 propensity score-matched controls, the mean weight loss over one year was 3.1 pounds in treated patients and 2.5 pounds in controls (p = 0.02) [<a href="#rid33">33</a>]. The proportion of patients who developed significant weight loss (10 pounds or more over one year) was also significantly higher in treated patients (29 versus 23 percent). In a meta-analysis of nine placebo-controlled randomized trials with a median follow-up of five months, the risk of any weight loss was twofold higher in patients randomized to receive a cholinesterase inhibitor (6 versus 3 percent; odds ratio [OR] 2.18, 95% CI 1.50-3.17) [<a href="#rid34">34</a>].</p><p>In patients who are noted to be losing weight while on a cholinesterase inhibitor, we typically pursue nutritional counseling before stopping therapy and monitor the trend in weight over time. AD is often associated with anosmia, which detracts from taste. Enhancing the taste of food with spices, sweet and sour flavoring, or soy sauce can help with appetite. For patients with comorbid depression, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> is a good choice of antidepressant because it can augment appetite.</p><p class="headingAnchor" id="H2076322556"><span class="h3">Bradycardia and hypotension</span><span class="headingEndMark"> — </span>Bradycardia, heart block, and syncope can arise due to enhanced vagal tone. Cholinergic therapy should be discontinued in patients who develop symptomatic bradycardia and/or hypotension for which no other addressable cause is identified (eg, concomitant antihypertensive therapy). Cholinesterase inhibitors should be avoided in patients with baseline bradycardia or known cardiac conduction system disease. (See <a class="local">'Contraindications and precautions'</a> above.)</p><p>In one population-based cohort, the incidence of hospitalization for syncope was 3.2 events per 100 person-years for individuals taking cholinesterase inhibitors (68 percent were taking <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>) [<a href="#rid24">24</a>]. This event rate was 1.7 times higher than in a control group. Similarly, a meta-analysis of 54 randomized trials found that cholinesterase inhibitors were associated with 1.5-fold greater risk of syncope than placebo [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2788142307"><span class="h3">Sleep disturbances</span><span class="headingEndMark"> — </span>Insomnia, vivid dreams, and other sleep disturbances may be more common with <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> than the other two drugs. If vivid dreams or nightmares arise on donepezil, switching to morning dosing or to an alternative drug may help [<a href="#rid32">32</a>].</p><p>Additional strategies for the management of sleep disturbances in patients with dementia are reviewed separately. (See  <a class="medical medical_review" href="/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Management'</a>.) </p><p class="headingAnchor" id="H4120545855"><span class="h1">FOLLOW-UP AND MONITORING</span><span class="headingEndMark"> — </span>Patients who are started on a cholinesterase inhibitor should be seen for follow-up at three and six months to assess drug tolerance and response. A phone call at two weeks can be useful to troubleshoot early side effects. Patients on a stable dose of drug are then seen every 6 to 12 months thereafter. Routine laboratory monitoring is not required for any of the cholinesterase inhibitors.</p><p class="headingAnchor" id="H2646605246"><span class="h2">Assessment of response</span><span class="headingEndMark"> — </span>Response to cholinesterase inhibitors can be subtle and gradual. We typically counsel patients and families to anticipate a six-month trial before making a decision about whether the medication is helping or not.</p><p>The Mini-Mental State Examination (MMSE) is not specific enough for following response; we generally use a combination of naming, recall of a four-word list or story at 30 seconds and five minutes, and semantic fluency (eg, naming as many animals as possible in one minute). The Montreal Cognitive Assessment (MoCA) can be administered at each visit to track change over time. The MoCA is accessible online and in multiple languages at <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.mocatest.org&amp;token=SAus%2FQEn5pFw2nQERKppCngupe7hR7SbPxeptx3hV9w%3D&amp;TOPIC_ID=5072" target="_blank">www.mocatest.org</a>. It is a 30-point test that takes approximately 10 minutes to administer. Other brief cognitive tests are reviewed separately. (See  <a class="medical medical_review" href="/d/html/14067.html" rel="external">"The mental status examination in adults", section on 'Cognitive screening tests'</a>.)</p><p>Caregiver impression of change, behavioral symptoms, sleep, and other neuropsychiatric symptoms should also be assessed at each visit. (See  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia", section on 'Symptom assessment'</a>.)</p><p>There is conflicting evidence that pharmacogenetics may influence the response to cholinesterase treatment, such that some patients are either hyper- or hypometabolizers of these agents [<a href="#rid36">36-39</a>]. As an example, some studies have suggested that patients with a specific <em>CYP2D6</em> allele have a poorer response to <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> treatment, particularly if they also have the apolipoprotein E (<em>APOE</em>) epsilon 4 allele [<a href="#rid37">37,39</a>]. However, these associations do not appear to have a consistent effect on treatment response and have no clear association with adverse effects. Thus, we do not test for these alleles and instead assess and respond to the observed clinical effects and/or side effects.</p><p class="headingAnchor" id="H691890260"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>There is no consensus on how long to continue cholinesterase inhibitors in patients who are tolerating therapy, and even patients who respond initially will ultimately progress.</p><p class="headingAnchor" id="H225735465"><span class="h3">Patients who do not respond initially</span><span class="headingEndMark"> — </span>Since cholinesterase inhibitors are a symptomatic treatment and not disease modifying, some clinicians, patients, and families choose to stop treatment after a six-month trial if there has been no subjective or objective improvement. Unless the medication is already at the lowest dose, it should be tapered by 50 percent for two to three weeks before stopping to minimize risk of worsening. An alternative cholinesterase inhibitor is not typically used in this setting unless a patient is unable to achieve a target dose on the initial chosen drug due to side effects or formulation. <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> can be added or substituted in patients with moderate to severe dementia. (See <a class="local">'Role of memantine'</a> below.)</p><p>Others feel that it is not possible to determine which patients are responders based on initial response to medication and therefore suggest continuing medication as long as the patient agrees to it and tolerates it [<a href="#rid40">40</a>]. Support for this approach is also drawn from a clinical trial of 295 patients with moderate to severe AD who were already taking <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, which compared the efficacy of four treatment strategies: no therapy (donepezil discontinued), donepezil continued alone, donepezil continued with <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> added, and memantine therapy alone [<a href="#rid41">41,42</a>]. After one year, patients assigned to receive donepezil therapy had, on average, a higher score on the MMSE (1.9 points) and a better score on the Bristol Activities of Daily Living Scale (BADLS; 3.0 points) compared with those not receiving donepezil. The average differences in the MMSE score, but not the BADLS, met the prespecified threshold considered by the investigators to be clinically important. The trial was stopped early due to slow recruitment. A post hoc analysis suggested that discontinuation of donepezil might increase the risk of nursing home placement over the next 12 months, but not over the prespecified four-year follow-up period [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1804037315"><span class="h3">Other reasons for discontinuation</span><span class="headingEndMark"> — </span>Aside from lack of perceived benefit, other reasons for discontinuation of cholinesterase inhibitors include:</p><p class="bulletIndent1"><span class="glyph">●</span>Intolerable side effects despite dose reduction. If the main reason for discontinuation of a drug is gastrointestinal side effects, sometimes switching to a different formulation or drug can help. <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> is also an option in patients with moderate to severe disease and may be better tolerated. (See <a class="local">'Approach to common side effects'</a> above and <a class="local">'Role of memantine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rate of cognitive, functional, or behavioral decline is greater on treatment compared with pretreatment baseline. Of note, fluctuations in cognition and behavior are common in patients with dementia and are often multifactorial. An approach to the evaluation and management of neuropsychiatric symptoms of dementia is presented separately. (See  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities or nonadherence make continued use of the drug unacceptably risky or futile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression to an advanced stage of dementia (eg, Functional Assessment Stage 7 (<a class="graphic graphic_table graphicRef89837" href="/d/graphic/89837.html" rel="external">table 2</a>)), in which there is little hope for a clinically meaningful benefit to continued therapy. (See  <a class="medical medical_review" href="/d/html/86250.html" rel="external">"Care of patients with advanced dementia", section on 'Discontinuing chronic medications'</a>.)</p><p></p><p class="headingAnchor" id="H2203127316"><span class="h3">Patients who worsen when drug is stopped</span><span class="headingEndMark"> — </span>Occasionally patients will worsen after stopping therapy, even when appropriately tapered over a two- to three-week period [<a href="#rid43">43-45</a>]. It is not clear if this is a sign that they benefited from the medication, but we generally reintroduce it when clinical decline is closely temporally linked with medication withdrawal. While data from clinical trials suggested that treatment gaps (periods in which the patient did not take cholinesterase inhibitor) were associated with worse outcomes, a large observational study of older adult patients prescribed cholinesterase inhibitors found that the risk of institutionalization or death did not appear to be increased among those who experienced treatment gaps [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H3798162770"><span class="h2">Role of memantine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> is commonly added to cholinesterase inhibitor therapy when patients reach a moderate stage of AD (MMSE ≤18), based on moderate-quality data that the combination therapy leads to modest symptomatic benefits on cognition and behavior. Memantine can also be used as a single agent among patients who do not tolerate cholinesterase inhibitors. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Memantine'</a>.)</p><p class="headingAnchor" id="H3950635511"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H12047226"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15523.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16421.html" rel="external">"Patient education: Caring for someone with Alzheimer disease or dementia (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/736.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Cholinesterase inhibitors target the acetylcholine deficit arising from loss of neurons in the brain. These are symptomatic therapies and are not believed to be neuroprotective or to alter the disease trajectory. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>–<strong> </strong>Cholinesterase inhibitors have been most extensively evaluated in patients with Alzheimer disease (AD) dementia. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Cholinesterase inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Lower-quality data support a trial of a cholinesterase inhibitor in patients with other forms of dementia, including dementia with Lewy bodies (DLB), vascular dementia, and Parkinson disease dementia. Recommendations for treatment of these disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies", section on 'Cholinesterase inhibitors'</a> and  <a class="medical medical_review" href="/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia", section on 'Cholinesterase inhibitors'</a> and  <a class="medical medical_review" href="/d/html/5089.html" rel="external">"Cognitive impairment and dementia in Parkinson disease", section on 'Cholinesterase inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Cholinesterase inhibitors are contraindicated in patients with baseline bradycardia or known cardiac conduction system disease (eg, sick sinus syndrome, incomplete heart block) due to risk of syncope, falls, and fractures.</p><p></p><p class="bulletIndent1">They should be used with caution in combination with drugs that induce bradycardia or alter nodal conduction. (See <a class="local">'Contraindications and precautions'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – The choice among <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>, and <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> is based upon ease of use, individual patient tolerance, cost, and clinician and patient preference; efficacy appears to be similar (<a class="graphic graphic_table graphicRef63284" href="/d/graphic/63284.html" rel="external">table 1</a>). (See <a class="local">'Choice of drug'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">Donepezil</a> is available as a once-daily tablet and a once-daily disintegrating sublingual tablet. The starting dose is 5 mg once daily. No dose adjustments are needed for renal or hepatic impairment. (See <a class="local">'Donepezil'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">Galantamine</a> is available as a once-daily extended-release capsule and twice-daily tablet or solution. The starting dose is 8 mg once daily for the extended-release capsule (4 mg twice daily for immediate release), with meals. Dose adjustments are required for renal or hepatic impairment. (See <a class="local">'Galantamine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">Rivastigmine</a> is available as an oral capsule or solution (starting dose 1.5 mg twice daily) and as a daily transdermal patch (starting dose 4.6 mg/24 hours). The patch is preferred due to superior pharmacokinetics and tolerability; it requires dose adjustments for hepatic impairment and low body weight. (See <a class="local">'Rivastigmine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>–<strong> </strong>The most common side effects of cholinesterase inhibitors are diarrhea, nausea, and vomiting. The toxicity is dose related and often resolves with time or dose reduction. Additional side effects include anorexia and weight loss, bradycardia and hypotension, syncope, and sleep disturbances. (See <a class="local">'Approach to common side effects'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – There is no consensus on how long to continue cholinesterase inhibitors in patients who are tolerating therapy. Even patients who respond initially will ultimately decline. Some clinicians, patients, and families choose to stop treatment after six months if there is no improvement. Others feel that it is not possible to determine which patients are responders based on initial response and continue medication as long as the patient agrees and tolerates it. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1">Other reasons for discontinuation include poor tolerance despite dose reduction or drug switching, comorbidities or nonadherence that make continued use risky or futile, and progression to an advanced stage of dementia. (See <a class="local">'Other reasons for discontinuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to discontinuation</strong> – Unless the medication is already at the lowest dose, it should be tapered by 50 percent for two to three weeks before stopping to minimize risk of worsening.</p><p></p><p class="bulletIndent1">We generally reintroduce therapy if a clinical decline occurs shortly after medication withdrawal. (See <a class="local">'Patients who worsen when drug is stopped'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004; 292:2901.</a></li><li><a class="nounderline abstract_t">Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283.</a></li><li><a class="nounderline abstract_t">Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7:159.</a></li><li><a class="nounderline abstract_t">Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1154.</a></li><li class="breakAll">Guideline Watch (October 2014): Practice guideline for the treatment of patients with Alzheimer's disease and other dementias. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/alzheimerwatch.pdf.</li><li><a class="nounderline abstract_t">Gauthier S, Patterson C, Chertkow H, et al. 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Can J Neurol Sci 2012; 39:S1.</a></li><li class="breakAll">NICE Guidance: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. https://www.nice.org.uk/guidance/ta217/chapter/1-Guidance.</li><li><a class="nounderline abstract_t">O'Brien JT, Burns A, BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25:997.</a></li><li><a class="nounderline abstract_t">Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010; 17:1236.</a></li><li><a class="nounderline abstract_t">Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012; 19:1159.</a></li><li><a class="nounderline abstract_t">Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20:777.</a></li><li><a class="nounderline abstract_t">Ancoli-Israel S, Amatniek J, Ascher S, et al. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord 2005; 19:240.</a></li><li><a class="nounderline abstract_t">Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 2006; 22:483.</a></li><li><a class="nounderline abstract_t">Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21:1317.</a></li><li><a class="nounderline abstract_t">Campbell NL, Perkins AJ, Gao S, et al. Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial. J Am Geriatr Soc 2017; 65:1497.</a></li><li><a class="nounderline abstract_t">Cui CC, Sun Y, Wang XY, et al. The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis. Medicine (Baltimore) 2019; 98:e16091.</a></li><li><a class="nounderline abstract_t">Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56:441.</a></li><li><a class="nounderline abstract_t">Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther 2010; 32:1234.</a></li><li><a class="nounderline abstract_t">Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50:136.</a></li><li><a class="nounderline abstract_t">Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58:427.</a></li><li><a class="nounderline abstract_t">Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57:481.</a></li><li><a class="nounderline abstract_t">Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57:489.</a></li><li><a class="nounderline abstract_t">Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc 2009; 57:1997.</a></li><li><a class="nounderline abstract_t">Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009; 169:867.</a></li><li class="breakAll">http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/aricept-eng.php.</li><li><a class="nounderline abstract_t">Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment. BMJ 2005; 330:276.</a></li><li><a class="nounderline abstract_t">Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22:456.</a></li><li><a class="nounderline abstract_t">Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69:S14.</a></li><li><a class="nounderline abstract_t">Isaacson RS, Ferris S, Velting DM, Meng X. Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease. Am J Alzheimers Dis Other Demen 2016; 31:270.</a></li><li><a class="nounderline abstract_t">Novartis Exelon labeling update reflects report of esophageal rupture. The Pink Sheet 2001; 63:24.</a></li><li><a class="nounderline abstract_t">Feldman HH, Lane R, Study 304 Group. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78:1056.</a></li><li><a class="nounderline abstract_t">Regenold WT, Loreck DJ, Brandt N. Prescribing Cholinesterase Inhibitors for Alzheimer Disease: Timing Matters. Am Fam Physician 2018; 97:700.</a></li><li><a class="nounderline abstract_t">Sheffrin M, Miao Y, Boscardin WJ, Steinman MA. Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System. J Am Geriatr Soc 2015; 63:1512.</a></li><li><a class="nounderline abstract_t">Soysal P, Isik AT, Stubbs B, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2016; 87:1368.</a></li><li><a class="nounderline abstract_t">Kim DH, Brown RT, Ding EL, et al. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 2011; 59:1019.</a></li><li><a class="nounderline abstract_t">Miranda LF, Gomes KB, Silveira JN, et al. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study. J Alzheimers Dis 2015; 45:609.</a></li><li><a class="nounderline abstract_t">Xiao T, Jiao B, Zhang W, et al. Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis. CNS Drugs 2016; 30:899.</a></li><li><a class="nounderline abstract_t">Chianella C, Gragnaniello D, Maisano Delser P, et al. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 2011; 67:1147.</a></li><li><a class="nounderline abstract_t">Pilotto A, Franceschi M, D'Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009; 73:761.</a></li><li><a class="nounderline abstract_t">Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017; 390:2673.</a></li><li><a class="nounderline abstract_t">Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366:893.</a></li><li><a class="nounderline abstract_t">Howard R, McShane R, Lindesay J, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol 2015; 14:1171.</a></li><li><a class="nounderline abstract_t">Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63:214.</a></li><li><a class="nounderline abstract_t">Rainer M, Mucke HA, Krüger-Rainer C, et al. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm (Vienna) 2001; 108:1327.</a></li><li><a class="nounderline abstract_t">O'Regan J, Lanctôt KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry 2015; 76:e1424.</a></li><li><a class="nounderline abstract_t">Pariente A, Fourrier-Réglat A, Bazin F, et al. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology 2012; 78:957.</a></li></ol></div><div id="topicVersionRevision">Topic 5072 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598922" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mixed dementia: emerging concepts and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965273" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809936" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342679" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342679" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23073396" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23073396" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088041" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20831773" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : EFNS guidelines for the diagnosis and management of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22891773" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875613" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16327351" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16574032" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083542" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295141" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31277107" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166542" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20678673" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443470" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255446" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502917" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502918" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19793162" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433698" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433698" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695272" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Regulatory authorities review use of galantamine in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17380489" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646619" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371345" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Novartis Exelon labeling update reflects report of esophageal rupture</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353259" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30215946" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prescribing Cholinesterase Inhibitors for Alzheimer Disease: Timing Matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26234945" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27261502" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21649634" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589728" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27282366" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21630031" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738170" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28735855" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dementia prevention, intervention, and care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22397651" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Donepezil and memantine for moderate-to-severe Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26515660" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277611" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11768631" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646039" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422894" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
